Molecular Targeting Technologies, Inc. (MTTI) and National Health
Research Institutes (NHRI), Taiwan announced today that the two parties
have formed a joint collaboration in developing novel cancer
therapeutics, using the proprietary DPA delivery technology to carry
anticancer drugs that can be specifically delivered to and released at
the tumor sites. This collaboration has recently successfully achieved
proof-of-concept in preclinical xenograft models and is now moving
toward the next major milestone, which is the selection of a candidate
for clinical development.
This technology is based on an unexpected discovery that certain
dipicolyamine derivatives are effective in delivering a therapeutic
agent to target disease sites that have phosphatidylserine exposed on
the external surfaces of the cell membranes.
Chuan Shih, Ph.D., Director of Institute of Biotechnology and
Pharmaceutical Research (IBPR) of NHRI said, "We are delighted to have
this opportunity to work with MTTI and apply the unique DPA technology
as a novel and specific deivery system for the development of novel
Chris Pak, President and CEO of MTTI said, "We are greatly encouraged by
the robust activities and distinct advantages of this novel class of
DPA-drug conjugates compared to conventional therapeutic agents in the
colon cancer model. We are in the process of assessing the effectiveness
of this new therapeutic agent in other tumors as well."
National Health Research Institutes
National Health Research Institutes (NHRI), established in January 1996,
is an autonomous research organization under the supervision and support
of the government. NHRI is dedicated to improve the health and
well-being of the people, enhance the quality of biomedical research and
medical care, develop medical and pharmaceutical technology as well as
train and cultivate biomedical researchers. Research units including 7
institutes, 3 centers and 1 division and core facilities such as Cell
Bank, Digital Library and Bioinformatics are set up for state-of-the-art
medical research. Scientists at NHRI conduct mission-oriented medical
research and investigate many aspects of the basic biomedical sciences,
as well as specific diseases. These range from the common problems such
as aging, cancer, infectious diseases, mental disorders, occupational
diseases, to health policy.
Molecular Targeting Technologies, Inc.
Molecular Targeting Technologies, Inc. (MTTI) is a privately held
biotechnology company primarily focused on the acquisition and
development of novel technologies for treatment and diagnosis of human
diseases. MTTI has licensed and is developing two major technology
platforms to provide: (i) novel small molecule drug conjugate (SMDC)
cancer therapeutics, and (ii) in vivo imaging agents. For the in vivo
imaging platform, two lead product candidates, 99mTc-Duramycin and
18F-TumorVue, are being developed as novel apoptotic cell-imaging agents
for the detection of atherosclerotic plaque, cardiotoxicity and the
effective monitoring of cancer therapy.
[ Back To NFVZone's Homepage ]